Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05525247 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
A Phase 1 study of Advanced Solid Tumor, sponsored by Selecxine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 420
- Enrollment target
- 9
- Study locations
NCT05525247: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Selecxine.
NCT05525247 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Selecxine. The registered enrollment target is 420 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (120% higher). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05525247, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Selecxine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 420 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination with gemcitabine, in patients with various advanced solid tumors.
Primary Outcome
Number of participants with DLTs of SLC-3010 treatment
Conditions Studied
Interventions
- DRUG SLC-3010
- COMBINATION_PRODUCT Gemcitabine
Study Locations (9)
Florida
- Selecxine Investigator site - Sarasota
Michigan
- Selecxine Investigator site - Detroit
Oklahoma
- Selecxine Investigator site - Oklahoma City
New South Wales
- Selecxine Investigator site - Waratah
Perth
- Selecxine Investigator site - Brentwood
Jongno-gu
- Selecxine Investigator site - Seoul
Seodaemun-gu
- Selecxine Investigator site - Seoul
Seongnam-si
- Selecxine Investigator site - Gyeonggi-do
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2022-12-21 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
What NCT05525247 shows while recruiting
NCT05525247 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (120% higher).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which SLC-3010 is the first listed.
NCT05525247 lists 9 locations in 9 states (Florida, Michigan, Oklahoma).
Frequently Asked Questions
What is clinical trial NCT05525247 about?
NCT05525247 is a clinical study titled "A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination". This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination with gemcitabine, in...
What is the current status of trial NCT05525247?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 420 participants. The study started on 2022-12-21. Estimated completion is 2028-01.
What conditions does trial NCT05525247 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT05525247?
The interventions under investigation include: SLC-3010 (DRUG), Gemcitabine (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05525247?
This trial is sponsored by Selecxine, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05525247 being conducted?
This trial has 9 study locations across Florida, Michigan, Oklahoma, New South Wales, Perth. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05525247's enrollment target sits among peer trials
420 18th of 189 higher than 171 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI